Acumen raises $20m Series A for Alzheimer's antibody
This article was originally published in Scrip
Acumen Pharmaceuticals completed the first closing a $20 million Series A funding round, which will be used to demonstrate proof of concept for the monoclonal antibody ACU-193 in the treatment of Alzheimer's disease by 2016.
You may also be interested in...
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.